A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles* (Corresponding Author), P M Calverley, Katia M.C. Verhamme, M. Dreher, Valentina Bayer, Asparuh Gardev, Alberto de la Hoz, Jadwiga A Wedzicha, David Price

*Corresponding author for this work

Research output: Contribution to conferenceAbstractpeer-review

Abstract

A possible mortality benefit of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA+LABA combination treatment is reported in patients with highly symptomatic chronic obstructive pulmonary disease (COPD) with a history of exacerbations (≥1 moderate/severe exacerbation in previous year). We compared the time to all-cause mortality with LAMA+LABA+ICS versus LAMA+LABA in patients with moderate-to- severe COPD and predominantly lower exacerbation risk.
Original languageEnglish
Number of pages1
Publication statusAccepted/In press - 13 Sep 2021
EventEastern Pulmonary Conference 2021 - Palm Beach, UNITED STATES
Duration: 30 Sep 20213 Oct 2021
https://easternpulmonaryconference.org

Conference

ConferenceEastern Pulmonary Conference 2021
CountryUNITED STATES
CityPalm Beach
Period30/09/213/10/21
Internet address

Fingerprint

Dive into the research topics of 'A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation'. Together they form a unique fingerprint.

Cite this